Abstract:Ethnopharmacological relevance: Guben Xiezhuo Decoction (GBXZD) is an herbal compound used to treat chronic kidney disease (CKD) under the guidance of traditional Chinese medicine (TCM). Its main components are Astragalus membranaceus (Fisch.) Bunge, Codonopsis pilosula (Franch.) Nannf., Centella asiatica (L.) Urb., Salvia miltiorrhiza Bunge, Cuscuta chinensis Lam., and Rheum palmatum L.. Clinical studies have shown that it can relieve fatigue, nausea and other symptoms and improve kidney function in patients; however, its specific mechanism of action requires further study. Aim of the study: Renal interstitial fibrosis (RIF) is the ultimate characteristic manifestation of various CKD, that cannot be cured, and appropriate treatments to delay its progression require further exploration. GBXZD, widely used in clinical practice for RIF treatment, can effectively relieve the syndrome in patients with CKD. However, the specific mechanism of action of GBXZD in RIF is unknown and requires further study. This study aimed to explore the specific effects of GBXZD on RIF through the regulation of M1 macrophages. Materials and methods: An in vivo RIF model was obtained through unilateral ureteral obstruction (UUO), and the Sprague-Dawley (SD) rats were randomly divided into sham operation, UUO, UUO + GBXZD-low dose (GBXZD-L) and UUO + GBXZD-high dose (GBXZD-H) groups. Pathological changes in rat kidney specimens were observed using hematoxylin and eosin (HE) and Masson staining. The expression of collagen I (COL I), fibronectin (FN), α-smooth muscle actin (α-SMA), interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumour necrosis factor-α (TNF-α) was detected using immunohistochemistry, and immunofluorescence was used to detect the expression of CD86 and inducible nitric-oxide synthase (iNOS) in kidney tissue. An in vitro experiment was performed using M1 polarization model in RAW264.7 macrophages induced by lipopolysaccharide (LPS). Cells were divided into control, LPS, LPS + GBXZD-low dose (GBXZD-L) and LPS + GBXZD-high dose (GBXZD-H) groups. The changes in expression of CD86, iNOS, IL-1β, IL-6, and TNF-α were measured using western blotting, flow cytometry, immunofluorescence and enzyme-linked immunosorbent assay (ELISA). We analyzed the action pathway of GBXZD in regulating M1 polarization of macrophages using antibody microarray and verified the results using western blotting. Results: Histopathological results showed that the UUO group exhibited significant fibrotic injury compared to the sham group. After GBXZD treatment, the degree of kidney injury, RIF, and inflammatory factor expression were lower than those in the UUO group. Compared with LPS-treated cells, the expression of the M1 markers CD86, iNOS, and pathway proteins Raf1 and p-Elk1 was down-regulated in RAW 264.7 cells treated with LPS and GBXZD. The secretion of the inflammatory factors IL-1β, IL-6, and TNF-α in the LPS group was more than that in the control group. However, the levels of these factors were significantly reduced in the GBXZD-H group compared to those in the LPS group. Conclusions: This study indicates that GBXZD ameliorates RIF and inhibits the inflammatory response and macrophage M1 polarization by a potential mechanism related to the downregulation of Raf1 and p-Elk1. GBXZD therefore has therapeutic potential value for patients with CKD.

Fraxinellone alleviates kidney fibrosis by inhibiting CUG-binding protein 1-mediated fibroblast activation.

In Vitro and In Vivo Antifibrotic Effects of Fraxetin on Renal Interstitial Fibrosis via the ERK Signaling Pathway

Fraxin Represses NF-κB Pathway Via Inhibiting the Activation of Epidermal Growth Factor Receptor to Ameliorate Diabetic Renal Tubulointerstitial Fibrosis.

Fraxin Promotes the Activation of Nrf2/ARE Pathway via Increasing the Expression of Connexin43 to Ameliorate Diabetic Renal Fibrosis

Fraxinellone alleviates colitis-related intestinal fibrosis by blocking the circuit between PD-1 + Th17 cells and fibroblasts

Natural compound fraxinellone ameliorates intestinal fibrosis in mice via direct intervention of HSP47-collagen interaction in the epithelium

Targeted inhibition of TGF-β type I receptor by AZ12601011 protects against kidney fibrosis

Fraxetin pretreatment alleviates cisplatin‐induced kidney injury by antagonizing autophagy and apoptosis via mTORC1 activation

A key role of CUG-binding protein 1 in HSC activation and liver fibrogenesis revealed by fraxinellone

Fluorofenidone Attenuates Tubulointerstitial Fibrosis by Inhibiting TGF-β1-Induced Fibroblast Activation

Transcriptomic Analysis of the Mechanisms of Alleviating Renal Interstitial Fibrosis Using the Traditional Chinese Medicine Kangxianling in a Rat Model

Fucoxanthin Alleviates Renal Fibrosis in Experimental Diabetic Nephropathy by Regulating P62/keap1/nrf2 Signaling and Improving Mitochondrial Damage

Chrysophanol-mediated trx-1 activation attenuates renal fibrosis through inhibition of the JNK/Cx43 signaling pathway

Farnesoid X Receptor Activation Protects Against Renal Fibrosis Via Modulation of Β-Catenin Signaling.

Natural Flavonoid Pectolinarigenin Alleviated Kidney Fibrosis Via Inhibiting the Activation of TGFβ/SMAD3 and JAK2/STAT3 Signaling.

Hepatoprotective Effect of Fraxin Against Carbon Tetrachloride-Induced Hepatotoxicity in Vitro and in Vivo Through Regulating Hepatic Antioxidant, Inflammation Response and the MAPK-NF-κB Signaling Pathway

Astaxanthin Protects Against Renal Fibrosis Through Inhibiting Myofibroblast Activation and Promoting CD8+ T Cell Recruitment.

Guben Xiezhuo Decoction inhibits M1 polarization through the Raf1/p-Elk1 signaling axis to attenuate renal interstitial fibrosis

BMP1 Inhibitor UK383,367 Attenuates Renal Fibrosis and Inflammation in CKD

A novel role of BK potassium channel activity in preventing the development of kidney fibrosis

The Notch γ-secretase inhibitor ameliorates kidney fibrosis via inhibition of TGF-β/Smad2/3 signaling pathway activation.